Report
Christophe-Raphaël Ganet

Sartorius Stedim Biotech : T4 2020 / FY 2020 toujours aussi robuste et léger effet momentum

>T4 2020 en ligne avec le CS - Le CA T4 se monte à 530.6 M€, soit +45.8% et +47% à tcc. L’EBITDA T4 ressort à 170 M€ (31% du CA).Sur l’année, les revenus de SSB atteignent donc 1 910 M€ (+34,6% dont +6% lié aux acquisitions) pour un EBITDA de 605 M€.Pour 2021, la société guide sur une croissance de 20% à 26% soit env. 2 294-2 410 M€e (CS : 2 363 M€e) et une marge de 32% (soit 734-770 M€e / CS : 742 M€e)Pour 2025, SSB vise un CA de 3,8 Md€ (vs 3,5 Md€ a...
Underlying
Sartorius Stedim Biotech SA

Sartorius Stedim Biotech is a provider of equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Co.'s solutions cover fermentation, filtration, purification, fluid management and lab technologies and membrane chromatography, including various conventional lab products to biopharmaceutical laboratories. Co.'s technologies, products and services are used to develop and manufacture medications and vaccines using biological methods. Co.'s products covers all upstream and downstream steps in the production of active pharmaceutical ingredients. It specializes in single-use products and offers technical consulting and services.

Provider
Oddo BHF
Oddo BHF

​Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

Analysts
Christophe-Raphaël Ganet

Other Reports on these Companies
Other Reports from Oddo BHF

ResearchPool Subscriptions

Get the most out of your insights

Get in touch